IDiyas

For the Inventor, By the Inventor

Seattle, WA, United States of America

Melanie K Spriggs

USPTO Granted Patents = 33 

Average Co-Inventor Count = 3.3

ph-index = 17

Forward Citations = 659(Granted Patents)


Company Filing History:

goldMedal32 out of 451 
 
Immunex Corporation
 patents
silverMedal1 out of 832,680 
Other
 patents

Years Active: 1996-2008

Loading Chart...
33 patents (USPTO):Explore Patents
1. 7432237 - Methods of treating asthma by administering interleukin-17 receptor (2008-10-07),
2. 7405270 - CD40-Ligand lacking native-pattern glycosylation (2008-07-29),
3. 7309489 - Mouse CD40 ligand-specific antibodies and hybridomas (2007-12-18),
4. 7273843 - Methods of treating allergy by administering interleukin-17 receptor (2007-09-25),
5. 7214497 - Viral encoded semaphorin protein receptor DNA and polypeptides (2007-05-08),
6. 6680057 - Methods of treating autoimmune disease by administering interleukin-17 receptor (2004-01-20),
7. 6670135 - Semaphorin polypeptides (2003-12-30),
8. 6613320 - Defective CD4+T-cells that express active CD40-L (2003-09-02),
9. 6562949 - Antibodies to viral encoded semaphorin protein receptor polypeptides (2003-05-13),
10. 6410711 - DNA encoding CD40 ligand, a cytokine that binds CD40 (2002-06-25),
11. 6391637 - Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells (2002-05-21),
12. 6290972 - Method of augmenting a vaccine response by administering CD40 ligand (2001-09-18),
13. 6264951 - Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L (2001-07-24),
14. 6197525 - Assay kits for detection and methods of inhibiting IL-17 binding (2001-03-06),
15. 6191104 - Methods of treating graft rejection with the IL-17 receptor (2001-02-20),

Title: **Melanie K. Spriggs: A Pioneer in Asthma Treatment Innovations**

Introduction

Melanie K. Spriggs, based in Seattle, WA, stands out as a prominent inventor in the field of immunology and respiratory health. With an impressive portfolio of 33 patents, her contributions have significantly advanced the understanding and treatment of asthma through innovative molecular techniques.

Latest Patents

Among Melanie's latest patents are groundbreaking methods for treating asthma by administering interleukin-17 receptor. This innovation presents isolated receptors for IL-17 and DNA encoding such receptors, which can be utilized to regulate immune responses effectively. Another notable patent involves a CD40-Ligand that lacks native-pattern glycosylation, providing polypeptides and DNA sequences that bind to the extracellular binding region of a CD40 receptor. These developments showcase Melanie's commitment to enhancing therapeutic options for patients suffering from asthma and other related conditions.

Career Highlights

Throughout her career, Melanie K. Spriggs has made remarkable strides, particularly during her tenure at Immunex Corporation. Her work has not only led to numerous patents but has also established her as a key figure in the biotechnology sector, focusing on immunological advancements.

Collaborations

Melanie has collaborated with notable professionals in her field, including William Christian Fanslow, III and Richard Jeffrey Armitage. These partnerships have been instrumental in propelling her research forward and driving innovations that benefit public health.

Conclusion

Melanie K. Spriggs exemplifies the spirit of innovation in medical science, particularly in the realm of asthma treatment. Her extensive patent portfolio and significant collaborations highlight her dedication to discovering novel therapies that can improve patient outcomes. As she continues her work, Melanie remains a vital asset to the scientific community and an inspiration to aspiring inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…